Latest news with #ChainReaction
Perth Now
a day ago
- Entertainment
- Perth Now
Ashlee Simpson reveals what Diana Ross is really like as a grandmother
Ashlee Simpson says Diana Ross is "so hands on" as a grandmother. The 40-year-old singer and reality star married the iconic musician's son Evan in 2014, and she has opened up about how the Chain Reaction hitmaker acts around her grandchildren. Asked how she is as a grandmother, Ashlee told E! News: "The best one! So hands on, and you wouldn't think of it like that. She's just about family." The loved up couple have kids Jagger Snow, eight, and Ziggy Blu, three, together, while the singer has son Bronx Mowgli, 15, from her previous marriage to Pete Wentz. Ashlee recently announced plans for a Las Vegas show, and she admitted she could be raiding Diana's closet for outfits. She quipped: "I would love to steal anything. Any time she's given me anything I'm like, 'Oh my God, this is the most beautiful piece!' "Her archive is beyond insane, so anything she's willing to give me I'll put on for good luck'... "We've seen in her Vegas so many times, she's always inspired me. She's a mom, she keeps it altogether, she's a grandma, she's Diana Ross!" Meanwhile, Ashlee also opened up on what their family is like over the holidays. She added: "They are [lit], the kids have so many cousins. We're all in one home, everyone's playing, the kids are all together. No one ever wants to leave." And while she's happy and in love with her "best friend" Evan after over a decade of marriage, her bond with sister Jessica Simpson is still a key part of her life. She said: "I think those things are just a part of what came with our lives. Together, we're always strong. "We definitely know how to overcome those things, and not harp on them, and not look back, and move forward. "We always have the best time together. Nobody knows you better than your sibling, you don't even have to say anything, you just get it."
Malaysian Reserve
6 days ago
- Business
- Malaysian Reserve
Gene Solutions and Shenzhen USK Bioscience Forge Strategic Partnership to Establish Next-Generation Sequencing Laboratory in Southern China
SINGAPORE, June 14, 2025 /PRNewswire/ — Gene Solutions, a leading multinational biotechnology company and Shenzhen USK Bioscience Co., Ltd. (USKBio), a prominent innovator in molecular diagnostics, have entered a strategic partnership through a Memorandum of Understanding (MOU). The landmark agreement paves the way for the establishment of a state-of-the-art next generation sequencing (NGS) laboratory in southern China, advancing localized oncology diagnostics. The collaboration will leverage USKBio's existing infrastructure, and Gene Solutions' advanced next-generation AI & genomics capabilities to jointly establish a next-generation sequencing (NGS) laboratory. The lab will focus on accelerating access to early cancer detection and molecular residual disease (MRD) monitoring using AI-powered circulating tumor DNA (ctDNA) technologies, tailored to address the unique clinical needs of southern China's healthcare landscape. USKBio brings extensive expertise in Polymerase Chain Reaction (PCR)-based In Vitro Diagnostics (IVD) and Good Manufacturing Practice (GMP)-certified production capabilities. Gene Solutions contributes its leadership in NGS-based oncology applications, highlighted by its groundbreaking SPOT-MAS test — Asia's first clinically validated multi-cancer early detection (MCED) assay, validated through a prospective study of 9,024 participants. Additionally, Gene Solutions recently published a real-world MRD study involving 623 patients across six cancer types—lung, colorectal, breast, gastric, liver, and ovarian—demonstrating the clinical utility of ctDNA for monitoring treatment response and assessing recurrence risk. This partnership will focus on localizing and validating these cutting-edge technologies for the Chinese market while fostering joint R&D and production of advanced IVD medical devices. This alliance represents a major step forward in delivering accessible, high-impact, personalized cancer diagnostics to a broader population in China. 'This partnership with USKBio allows us to move quickly in establishing a high-impact oncology hub in southern China,' said Dr. Nguyen Hoai Nghia, CEO and Co-founder at Gene Solutions. 'Together, we aim to bring early, accurate, and scalable cancer screening and diagnostics to more patients, ultimately improving cancer outcomes.' 'Gene Solutions and USKBio are highly complementary in their core technologies, regional markets, and business models.' said Dr. Yu Dehua, CEO at USKbio. 'This strategic collaboration will leverage both parties' strengths, creating strong synergies to deliver greater benefits to cancer patients across the Asia region.' The partnership also includes technology transfer, technical training, and joint commercialization efforts to ensure rapid deployment and widespread adoption of these advanced genomic tools. About Shenzhen USKBio Founded in August 2015, Shenzhen USKBio is a national high-tech biological enterprise established by leading Chinese and American scientists and entrepreneurs. Specializing in in vitro molecular diagnostics, USKBio integrates R&D, production, marketing, and medical testing services, with a robust presence in IVD reagents, diagnostic instruments, and testing services. Leveraging proprietary technologies such as Udx-PCR and Udx-MSP, the company offers innovative solutions for early cancer screening, precision diagnosis, and companion diagnostics. With over 36 authorized patents and collaborations across top hospitals and testing institutions in China, USKBio is a rising leader in the global molecular diagnostics industry, dedicated to advancing precision medicine. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific. Explore more information at:
Korea Herald
7 days ago
- Business
- Korea Herald
Gene Solutions and Shenzhen USK Bioscience Forge Strategic Partnership to Establish Next-Generation Sequencing Laboratory in Southern China
SINGAPORE, June 14, 2025 /PRNewswire/ -- Gene Solutions, a leading multinational biotechnology company and Shenzhen USK Bioscience Co., Ltd. (USKBio), a prominent innovator in molecular diagnostics, have entered a strategic partnership through a Memorandum of Understanding (MOU). The landmark agreement paves the way for the establishment of a state-of-the-art next generation sequencing (NGS) laboratory in southern China, advancing localized oncology diagnostics. The collaboration will leverage USKBio's existing infrastructure, and Gene Solutions' advanced next-generation AI & genomics capabilities to jointly establish a next-generation sequencing (NGS) laboratory. The lab will focus on accelerating access to early cancer detection and molecular residual disease (MRD) monitoring using AI-powered circulating tumor DNA (ctDNA) technologies, tailored to address the unique clinical needs of southern China's healthcare landscape. USKBio brings extensive expertise in Polymerase Chain Reaction (PCR) -based In Vitro Diagnostics (IVD) and Good Manufacturing Practice (GMP)-certified production capabilities. Gene Solutions contributes its leadership in NGS-based oncology applications, highlighted by its groundbreaking SPOT-MAS test — Asia's first clinically validated multi-cancer early detection (MCED) assay, validated through a prospective study of 9,024 participants. Additionally, Gene Solutions recently published a real-world MRD study involving 623 patients across six cancer types—lung, colorectal, breast, gastric, liver, and ovarian—demonstrating the clinical utility of ctDNA for monitoring treatment response and assessing recurrence risk. This partnership will focus on localizing and validating these cutting-edge technologies for the Chinese market while fostering joint R&D and production of advanced IVD medical devices. This alliance represents a major step forward in delivering accessible, high-impact, personalized cancer diagnostics to a broader population in China. "This partnership with USKBio allows us to move quickly in establishing a high-impact oncology hub in southern China," said Dr. Nguyen Hoai Nghia, CEO and Co-founder at Gene Solutions. "Together, we aim to bring early, accurate, and scalable cancer screening and diagnostics to more patients, ultimately improving cancer outcomes." "Gene Solutions and USKBio are highly complementary in their core technologies, regional markets, and business models." said Dr. Yu Dehua, CEO at USKbio. "This strategic collaboration will leverage both parties' strengths, creating strong synergies to deliver greater benefits to cancer patients across the Asia region." The partnership also includes technology transfer, technical training, and joint commercialization efforts to ensure rapid deployment and widespread adoption of these advanced genomic tools. About Shenzhen USKBio Founded in August 2015, Shenzhen USKBio is a national high-tech biological enterprise established by leading Chinese and American scientists and entrepreneurs. Specializing in in vitro molecular diagnostics, USKBio integrates R&D, production, marketing, and medical testing services, with a robust presence in IVD reagents, diagnostic instruments, and testing services. Leveraging proprietary technologies such as Udx-PCR and Udx-MSP, the company offers innovative solutions for early cancer screening, precision diagnosis, and companion diagnostics. With over 36 authorized patents and collaborations across top hospitals and testing institutions in China, USKBio is a rising leader in the global molecular diagnostics industry, dedicated to advancing precision medicine. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific.
Yahoo
7 days ago
- Business
- Yahoo
Gene Solutions and Shenzhen USK Bioscience Forge Strategic Partnership to Establish Next-Generation Sequencing Laboratory in Southern China
SINGAPORE, June 14, 2025 /PRNewswire/ -- Gene Solutions, a leading multinational biotechnology company and Shenzhen USK Bioscience Co., Ltd. (USKBio), a prominent innovator in molecular diagnostics, have entered a strategic partnership through a Memorandum of Understanding (MOU). The landmark agreement paves the way for the establishment of a state-of-the-art next generation sequencing (NGS) laboratory in southern China, advancing localized oncology diagnostics. The collaboration will leverage USKBio's existing infrastructure, and Gene Solutions' advanced next-generation AI & genomics capabilities to jointly establish a next-generation sequencing (NGS) laboratory. The lab will focus on accelerating access to early cancer detection and molecular residual disease (MRD) monitoring using AI-powered circulating tumor DNA (ctDNA) technologies, tailored to address the unique clinical needs of southern China's healthcare landscape. USKBio brings extensive expertise in Polymerase Chain Reaction (PCR)-based In Vitro Diagnostics (IVD) and Good Manufacturing Practice (GMP)-certified production capabilities. Gene Solutions contributes its leadership in NGS-based oncology applications, highlighted by its groundbreaking SPOT-MAS test — Asia's first clinically validated multi-cancer early detection (MCED) assay, validated through a prospective study of 9,024 participants. Additionally, Gene Solutions recently published a real-world MRD study involving 623 patients across six cancer types—lung, colorectal, breast, gastric, liver, and ovarian—demonstrating the clinical utility of ctDNA for monitoring treatment response and assessing recurrence risk. This partnership will focus on localizing and validating these cutting-edge technologies for the Chinese market while fostering joint R&D and production of advanced IVD medical devices. This alliance represents a major step forward in delivering accessible, high-impact, personalized cancer diagnostics to a broader population in China. "This partnership with USKBio allows us to move quickly in establishing a high-impact oncology hub in southern China," said Dr. Nguyen Hoai Nghia, CEO and Co-founder at Gene Solutions. "Together, we aim to bring early, accurate, and scalable cancer screening and diagnostics to more patients, ultimately improving cancer outcomes." "Gene Solutions and USKBio are highly complementary in their core technologies, regional markets, and business models." said Dr. Yu Dehua, CEO at USKbio. "This strategic collaboration will leverage both parties' strengths, creating strong synergies to deliver greater benefits to cancer patients across the Asia region." The partnership also includes technology transfer, technical training, and joint commercialization efforts to ensure rapid deployment and widespread adoption of these advanced genomic tools. About Shenzhen USKBio Founded in August 2015, Shenzhen USKBio is a national high-tech biological enterprise established by leading Chinese and American scientists and entrepreneurs. Specializing in in vitro molecular diagnostics, USKBio integrates R&D, production, marketing, and medical testing services, with a robust presence in IVD reagents, diagnostic instruments, and testing services. Leveraging proprietary technologies such as Udx-PCR and Udx-MSP, the company offers innovative solutions for early cancer screening, precision diagnosis, and companion diagnostics. With over 36 authorized patents and collaborations across top hospitals and testing institutions in China, USKBio is a rising leader in the global molecular diagnostics industry, dedicated to advancing precision medicine. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific. Explore more information at: View original content to download multimedia: SOURCE Gene Solutions Genomics Pte Ltd Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13-06-2025
- Business
- Yahoo
Chain Reaction: Dispatch Science CEO Arthur Axelrad on Turning Logistics into a ‘Customer Experience Engine'
Chain Reaction is Sourcing Journal's discussion series with industry executives to get their take on today's logistics challenges and learn about ways their company is working to keep the flow of goods moving. Here, Arthur Axelrad, co-founder & CEO of Dispatch Science, discusses how the transportation management company is leveraging artificial intelligence (AI)-powered solutions to streamline operations and provide real-time visibility for customers. Name: Arthur Axelrad More from Sourcing Journal US, Allies Warn of Russian Cyber Campaign Targeting Western Logistics Firms Logistics M&As: E2Open Taken Private in $2.1B Deal, UPS Sells Ware2Go to Stord US-Based Chinese Logistics Firms Caught Using Counterfeit USPS Labels Title: Co-founder & CEO Company: Dispatch Science What is Dispatch Science? Dispatch Science is a cloud-first logistics and delivery software platform and a leader in next-generation transportation management software for last-mile couriers and delivery businesses. We use the power of AI, algorithms and integrated route optimization to simplify and streamline all aspects of dispatching and delivery operations for on-demand and last-mile shippers, carriers and couriers. What industries do you primarily serve? We primarily serve courier and parcel delivery, medical and pharmaceutical logistics, retail and e-commerce and third-party logistics (3PLs) companies. Which industry do you think has the most to teach fashion about improving their supply chain logistics? I'd say that medical logistics is a good one to look to. When you're handling life-saving medications or organ transplants, you need to develop and uphold incredible precision surrounding the chain of custody—every item tracked from source to patient with complete auditable logs. Fashion brands, especially luxury and sustainability-focused ones, could learn so much from this. Imagine being able to prove the authentic journey of a limited-edition handbag or verify those sustainability claims everyone's making. The exception management protocols in medical are also fascinating—they have sophisticated workflows for when things go wrong, rather than scrambling to figure it out in the moment. For example, if a temperature-controlled pharmaceutical shipment goes outside the required range, there are predefined protocols: immediate alerts to all stakeholders, automatic rerouting to the nearest compliant facility, documentation requirements for regulatory compliance and clear escalation paths depending on the severity. Compare that to fashion, where a delayed shipment of limited-edition sneakers might trigger a flurry of panicked phone calls and improvised solutions. Medical logistics teaches you to plan for failure scenarios upfront, so when they happen—and they will—you have tested procedures that minimize impact and maintain service levels. What are the main things brands and retailers could do (or stop doing) right now that would immediately improve logistics? Replacing legacy electronic data interchange (EDI) systems with modern advanced passenger information (API) systems. I can't tell you how many companies I see still operating on batch processing that updates once or twice a day while their customers expect real-time everything. It's like trying to compete in Formula 1 with a horse and buggy! Even streamlining packaging can give immediate returns. We've seen clients substantially cut shipping costs by rightsizing boxes and ditching unnecessary materials. Above all, though, I'd encourage leaders to stop thinking of logistics as this necessary evil and start treating it as a customer experience engine instead. A delivery experience is often the last touchpoint a customer has with a brand, so they need to make it memorable for the right reasons. When it comes to creating efficiencies, there are quick wins and longer plays. What are a few things your company is doing to help its partners succeed on both fronts? For immediate impact, we insist on carriers using tech-enabled solutions with AI-based route optimization. This isn't just about transparency (though that's important), it's about real cost reduction through better routing. Automating customer notifications is another quick win that dramatically reduces support calls. Long-term, we're focused on building predictive analytics capabilities for demand and capacity planning. This helps get ahead of seasonal fluctuations rather than constantly reacting. The holy grail is of course end-to-end visibility with both upstream and downstream partners. When suppliers, carriers and customers are all connected through shared data, companies can best optimize the entire network rather than just their piece of it. Our platform is modular, too, so it scales with clients from startups to enterprise fleets. What is the one thing brands and retailers could be doing to make better use of technology to improve logistics? Integration, integration, integration! Most companies have these islands of technology: Their transportation management system (TMS) talks to their warehouse system, their inventory system talks to their point of sale (POS), but nothing talks to everything else. When you create a unified view of operations, however, you unlock optimization opportunities that weren't visible before. This integration enables AI-powered demand forecasting, dynamic pricing and real-time visibility platforms that actually improve customer communication and reduce failed deliveries. The technology exists, it's just a matter of connecting the dots. Are you optimistic about the state of supply chains in the next few years? I'm cautiously optimistic. Yes, we're dealing with unprecedented challenges like labor shortages, geopolitical instability and evolving consumer expectations. However, the rapid adoption of AI, automation and data-driven decision-making is creating much more resilient and adaptive supply chains. What gives me the most hope is seeing technology democratization happen in real-time. Smaller operators are gaining access to capabilities that were previously only available to enterprise companies. When a 50-truck carrier can compete on technology with a 5,000-truck fleet, it levels the playing field and drives innovation across the entire industry.
